dBET6
Cat. No.:YN430068
产品名称: | dBET6 |
CAS No.: | 1950634-92-0 |
Chemical Name: | (6S)-4-(4-chlorophenyl)-N-[8-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]octyl]-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide |
Synonyms: | |
分子量: | 841.37 |
分子式: | C₄₂H₄₅ClN₈O₇S |
SMILES: | O=C(NCCCCCCCCNC(COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O)=O)C[C@H]4C5=NN=C(C)N5C6=C(C(C)=C(C)S6)C(C7=CC=C(Cl)C=C7)=N4 |
存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
运输: | Room temperature in continental US; may vary elsewhere. |
产品描述: | dBET6 是一种高效的,选择性的,细胞透过的基于PROTAC技术的BET降解剂,IC50值为 14 nM,具有抗肿瘤活性。 |
IC50和靶点: | |
In Vitro: | |
In Vivo: | |
Clinical Trial: | |
Solvent & Solubility: |
Winter, G.E., Mayer, A., Buckley, D.L., et al.BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitmentMol. Cell67(1),5-18(2017)
Goracci, L., Desantis, J., Valeri, A., et al.Understanding the metabolism of proteolysis targeting chimeras (PROTACs): The next step toward pharmaceutical applicationsJ. Med. Chem.63(20),11615-11638(2020)